40
Anvion Bio raises $1M in first offering under Reg D 506(b)
Company raise · Raising · SAN DIEGO, CA · Form D filed 2026-10-07
Anvion Bio, a Delaware pharmaceutical corporation incorporated in 2026, is raising up to $1M under Regulation D 506(b). The company has sold $100K to one investor as of September 22, 2026.
Note: Company incorporated in 2026 and filed first Form D in October 2026; very early-stage issuer with minimal capital deployed to date.
First raise on EDGARoperating_company
Why now — by persona
- Executive & technical recruiting:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- B2B software & services sales:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Commercial banking / treasury:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- D&O and management-liability insurance:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
- Outsourced accounting / CFO:A concrete reason to call this issuer this week, citing the filing. Subscribe to unlock
People on the filing
| Larry Braga | Chief Executive Officer and Secretary |
| Kevin Ernst | Chief Financial Officer |
| Anastasia Bodan | Director |
Signed by Larry Braga, Chief Executive Officer.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans, or read it on EDGAR.